Supplemental Figure 1 Patient disposition in the study population. AE, adverse event; BIM, bimatoprost 0.03% ophthalmic solution; BIM PF, bimatoprost 0.03% preservative-free ophthalmic solution; ITT, intent-to treat population; PP, per-protocol population.



Supplemental Figure 2 Mean worse eye IOP at each time point, per-protocol population. Difference between groups <0.4 mmHg. BIM, bimatoprost 0.03% ophthalmic solution; BIM PF, bimatoprost 0.03% preservative-free ophthalmic solution; IOP, intraocular pressure.



Supplemental Figure 3 Overall severity grading of hyperaemia on biomicroscopic and macroscopic assessment in either treatment group. BIM, bimatoprost 0.03% ophthalmic solution; BIM PF, bimatoprost 0.03% preservative-free ophthalmic solution. Summarized by eye with most severe grade from 2–12 weeks; between-group difference: p=0.473 for biomicroscopy evaluation and p=0.765 for macroscopic evaluation of bulbar hyperaemia.